Credit Suisse Healthcare Conference

Transcription

1 Credit Suisse Healthcare Coferece Michael E. Kamarck, Ph.D. Executive Vice Presidet, Techical Ops ad Product Supply November 12, 2008

2 Forward-Lookig Statemet The statemets i this presetatio that are ot historical facts are forwardlookig statemets based o curret expectatios of future evets ad are subject to risks ad ucertaities that could cause actual results to differ materially from those expressed or implied by such statemets. These risks ad ucertaities iclude risks associated with the iheret ucertaity of the timig ad success of product research, developmet ad commercializatio (icludig with respect to the NDA filigs for Wyeth s pipelie products refereced i this presetatio), drug pricig ad paymet for Wyeth s products by govermet ad third-party payers, maufacturig, data geerated o the safety ad efficacy of Wyeth s products, the impact of competitive or geeric products, trade buyig patters, global busiess operatios, product liability ad other types of litigatio, the impact of legislatio ad regulatory compliace, itellectual property rights, strategic relatioships with third parties, evirometal liabilities, ad other risks ad ucertaities, icludig those detailed from time to time i Wyeth s periodic reports filed with the Securities ad Exchage Commissio, icludig Wyeth s curret reports o Form 8-K, quarterly reports o Form 10-Q ad aual reports o Form 10-K, particularly the discussio i Wyeth s aual report o Form 10-K uder the captio "Item 1A, Risk Factors." Wyeth assumes o obligatio to publicly update ay forward-lookig statemets, whether as a result of ew iformatio, future developmets or otherwise.

3 A Diversified Biopharmaceutical Compay

4 Wyeth s Diversificatio A Key Asset Diverse Scietific Platforms Pharmaceuticals, Biotechology, Vaccies Diverse Busiess Platforms Biotech, Vaccies, Nutritioals, Cosumer Healthcare, Aimal Healthcare = 60% of Reveue i 2008 Growig to 75% by 2012 % of Reveue 100% 80% 60% 40% 20% 5% 12% 7% 36% 40% 60% No- Traditioal Pharma Diverse Therapeutic Approaches Treatmet vs. Disease Prevetio 0% YTD 2008 Prevetative Therapies - Huma ad Aimal Vaccies, Ifat Formula, Vitamis, Supplemets Pharma Biotech/Vaccies Nutritioals Cosumer Aimal Health

5 Core Biotech/Vaccie Frachises with High Growth Potetial ~$6 Billio Global Sales i 2008 #1 Worldwide Biotech Brad $10 Billio RA/Psoriasis Biological Market Expasio by 2012 Maitai #1 Positio i Category Due to Established Safety ad Efficacy Profile 31 Natioal Immuizatio Programs i Place o the Market i 89 Coutries Prevar 13 Filig for Ifats 2009; For Adults 2010 Maufacturig Capacity Strog ad Growig 60 Millio Doses i 2008 Future Maufacturig Capacity growig to 120 Millio Doses Wyeth - A Leadig Biotech Compay Globally Biotech/Vaccie Reveue YTD08 = $6.3 Billio, +20%

6 Wyeth Biopharma Maufacturig Diverse Maufacturig Platforms With Idustry Leadig Capacities ad Capabilities

7 Traditioal Pharma vs. Biotech Drugs/Vaccies Size ad Complexity Traditioal Pharma Small Chemical Molecules Biotech Drugs & New Geeratio Vaccies 100 to 1000X Larger Maufactured By Chemistry By Livig Cells Sterility of Process Delivery Mechaism Chemical Coditios Ofte Kill Bacteria Usually Tablets or Capsules All Steps Support Bacterial Growth Ijected or Other Special Delivery Maturity of Idustry >100 Years ~25 Years Wyeth Has Bee A Leader i Biotech Maufacturig Sice 1983

8 Wyeth Biotech Network Algete Spai Adover MA Grage Castle Irelad Pearl River NY Saford NC Havat UK ESN rd Parties 3 rd We Have Ivested Over $3.5 Billio i Network Ifrastructure Betwee 2000 ad 2007 i Support of Product Lauch ad Growth I Parallel, We Have Focused o Process Developmet Workig o the Premise That Biology Will Trump Stailess Steel With These Improvemets, the Existig Ifrastructure Ca Sustai the Cotiued Growth

9 Biotech Process Developmet Over 25 Years of Biotech Developmet Experiece >500 R&D Scietists 30 Differet Protei Products Brought Ito the Cliic Drug Substace ad Drug Product Developmet Facilities Research Labs 140,000 Sq Ft Pilot Scale Laboratories i the U.S. ad Irelad Cliical Maufacturig Facilities i MA ad NC

10 Cell Lie Developmet Pre-adapted CHO Host Idustrialized ad Automated Cell Lie Developmet ad Costructio Proprietary Fermetatio Techology Icreases Outputs From: g/l g/l g/l g/l 2007 [i May this year] Wyeth recetly created a cell culture system that ca geerate 9 grams of protei per liter of culture. Just four years ago, the stadard was 1 gram per liter. Nature Biotechology, September 2006

11 Bioreactor ad Purificatio Process Developmet Bioreactor Techology Proprietary, Defied Medium (Aimal Protei-free) Capable of Supportig Highest-desity Cultures Purificatio Techology Proprietary 2-colum MAb Purificatio Process Seamless Techical Trasfer of Process From Lab Bech to Maufacturig

12 Cliical Productio Suites 38,000 sq ft cgmp Multiproduct Maufacturig Equipmet/cGMP Systems to Maufacture Two Products Simultaeously Cell Culture Bioreactor Hall 1 X 6000 L 2 X 2500 L 1 X 500 L Purificatio Suites Match Bioreactor Capacity Support up to Te Campaigs Per Year for Both Cliical ad Future Commercial Products

13 Idustry-Leadig Platform Techology Upstream ad Dowstream Stadard Process Platform Established All Cell Lies Derived From Same Host All Proteis Produced From the Idetical Process Flow Usig the Same Raw Materials, Filters, Buffers, Resis 35% Reductio i Gee to IND Timelie Product Chageover i Days Sigle Facility Cofiguratio Ca Maufacture All Pipelie ad Commercial Products Wyeth Received the 2008 ACS Idustrial Biotechology Award Give by the Biotechology Divisio of the America Chemical Society Hoorig Distiguished Idustrial Accomplishmets i Biotechology Awarded to Wyeth: i Recogitio of Their Achievemets i Implemetig Idustry-leadig Platform Techology

14 Biology Trumps Stailess Steel Our Ivestmets Are i Process Stadardizatio ad Upstream/dowstream Process Efficiecies ad Yields We Have Implemeted the Platform For All Our Pipelie Products We Have Established a Proprietary Portfolio of Process Techologies We Have Utilized Our Techology Advaces i Improvig Our Existig Commercial Products

15 Biology Trumps Stailess Steel: Commercial Examples Product New Yields Approval Date Ebrel 150% Feb EMEA Xytha 200% Feb US BMP-2 >200% Nov 2007 EMEA March US Meets Projected Upside Demad Without Additioal Capital Ivestmet Icreases Capacity for Pipelie Products Improves Plat ad Product Cost Structure

16 Have Developed Process for Prevar 13v Produced 13v Cliical Trial Material; Phase 3 Trials Have Bee Successfully Completed Ivested i Staff ad Equipmet i Five Facilities i Support of Lauch I 2008, We Maufactured Lauch Supply of 13v From All Facilities We Have Completed 1200 Techical Documets i Support of Our Filig for Ifats Plaed by Early 2009 We Have Idetified Process Improvemets to Allow Us to Ultimately Maufacture up to 120 MM Doses of 13v From Our Existig Facilities

17 Stadardized Techology Platforms for Traditioal Pharma Products Miimize Capital Ivestmet Through Utilizatio of Oe Multi-product Lauch Module vs. Buildig Multiple Product-dedicated Modules Improve Existig Large Volume Asset Utilizatio by Leveragig Existig Ifrastructure Customizig API to Drive Stadard Formulatios Improve Our Flexibility to Expad/Cotract Capacity i Aligmet With Product Life Cycle Alig With the Prove Value Demostrated i Biotech Stadardizatio

18 Stadard Platforms Selected Based o Log Term Maufacturig Ease ad Network Fit H Tablet: Wet graulatio Tablet: Direct compressio Network Fit Capsule: Liquid filled Modify Excipiets or API Properties (Co-Labs) Modify or Outsource Special Formulatio Requiremets L Maufacturig Ease/Cost Advatage H

19 Wyeth: Positioig Itself for Future Growth Diversified by Busiess Prescriptio, Cosumer, Aimal Health Primary Product Egies Cotiue to Offer Growth Opportuities Ebrel, Prevar, Nutritioals New Product Lauches Cotributig to Reveue Growth Prove Capability i Three R&D Platforms ad Prove Ability to Successfully Commercialize ad Efficietly Maufacture Biotech, Vaccie ad Traditioal Pharma Pipelie Offers Rage of Optios Icludig Both Near-Term ad Blockbuster Cadidates Positioed to Take Advatage of Global Growth Opportuities Wyeth: A Diversified Biopharmaceutical Compay